
|Articles|February 1, 2005
Modified implant technique may minimize problems with miniature shunt
New Orleans—The ExPRESS miniature glaucoma shunt (Optonol Ltd., Neve Ilan, Israel; marketed by CIBA Vision, Duluth, GA), originally intended to be placed through the limbus and under a conjunctival flap, produced significant IOP lowering yet an unacceptable high rate of complications. So researchers are now investigating placement of the device under a scleral flap, according to Marlene R. Moster, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


